Skip to main content
TipRanks
Go Ultimate75% OFF

4D Molecular Therapeutics (FDMT) Ownership - Who Owns 4D Molecular Therapeutics?

534 Followers

4D Molecular Therapeutics (FDMT) Ownership Overview

  • 1.64% Insiders
  • 14.21% Mutual Funds
  • 10.84% Other Institutional Investors
  • 16.52% ETFs
  • 56.80% Public Companies and Individual Investors

The ownership structure of 4D Molecular Therapeutics (FDMT) stock is a mix of institutional, retail, and individual investors. Approximately 41.56% of the company’s stock is owned by Institutional Investors, 1.64% is owned by Insiders, and 56.80% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Recent Insider Trading Activity
DateNameActivityValue
Jun 24, 2026Scott Bizily$117,720
Dec 18, 2025Scott Bizily$17,822

Recent Hedge Fund Trading Activity

Recent Hedge Fund Trading Activity
DateFirmActivityValue
Jun 30, 2026Graham Capital Management, L.p.$159,640
Jun 30, 2026Fisher Asset Management Llc$874,488
Jun 30, 2026 $60,462,585

Top Shareholders

FDMT top shareholders
Holder# of SharesType% HoldingValue
Peter Kolchinsky5,049,779Institution9.14%61,758,797
BlackRock, Inc.4,724,904Institution8.55%57,785,576
Vanguard2,627,663Institution4.76%32,136,318
Ishares2,325,558Institution4.21%28,441,574
Vanguard Index Funds2,049,012Institution3.71%25,059,417
Spdr1,651,765Institution2.99%20,201,086
Janus Investment Fund788,444Institution1.43%9,642,670
Xtrackers739,927Institution1.34%9,049,307
David Kirn709,153Insider1.28%8,672,941
T. Rowe Price Small-cap Stock Fund, Inc.681,919Institution1.23%8,339,869

Top Mutual Fund Holders

FDMT top mutual fund holders
Holder# of SharesType% HoldingValue
Vanguard Index Funds2,049,012Institution3.71%25,059,417
Janus Investment Fund788,444Institution1.43%9,642,670
T. Rowe Price Small-cap Stock Fund, Inc.681,919Institution1.23%8,339,869
Fidelity Salem Street Trust571,734Institution1.03%6,992,307
Tiaa-cref Funds564,837Institution1.02%6,907,957
T. Rowe Price Small-cap Value Fund, Inc.455,274Institution0.82%5,568,001
Fidelity Concord Street Trust376,588Institution0.68%4,605,671
T. Rowe Price Equity Funds, Inc.368,160Institution0.67%4,502,597
Dfa Investment Dimensions Group Inc323,090Institution0.58%3,951,391
Blackrock Funds319,756Institution0.58%3,910,616

Top ETF Holders

FDMT top ETF holders
Holder# of SharesType% HoldingValue
Vanguard Total Stock Market ETF, VTI ETF1,588,533Institution2.88%22,731,907
SPDR S&P BIOTECH ETF, XBI ETF1,220,516Institution2.21%15,854,503
iShares Russell 2000 ETF, IWM ETF1,175,968Institution2.13%14,246,852
Vanguard Extended Market ETF, VXF ETF502,016Institution0.91%7,183,849
iShares Russell 2000 Value ETF, IWN ETF426,704Institution0.77%5,169,519
iShares Biotechnology ETF, IBB ETF386,456Institution0.70%4,681,914
Dimensional U.S. Small Cap ETF, DFAS ETF301,332Institution0.55%3,914,303
SPDR S&P Kensho New Economies Composite ETF, KOMP ETF283,791Institution0.51%3,686,445
Vanguard Russell 2000 ETF, VTWO ETF266,740Institution0.48%3,817,049
Fidelity Enhanced Small Cap ETF, FESM ETF233,095Institution0.42%3,027,904

FAQ

Who Owns 4D Molecular Therapeutics (FDMT)?
According to the latest TipRanks data, approximately 41.56% of the company's stock is held by institutional investors, 1.64% is held by insiders, and 56.80% is held by public companies and individual investors.
What percentage of 4D Molecular Therapeutics (FDMT) stock is held by institutional investors?
According to the latest TipRanks data, approximately 41.56% of 4D Molecular Therapeutics (FDMT) stock is held by institutional investors: 14.21% by mutual funds, 16.52% by ETFs and 10.84% by other institutional investors.
What percentage of 4D Molecular Therapeutics (FDMT) stock is held by retail investors?
According to the latest TipRanks data, approximately 56.80% of 4D Molecular Therapeutics (FDMT) stock is held by public companies and individual investors.
Who owns the most shares of 4D Molecular Therapeutics (FDMT)?
Peter Kolchinsky owns the most shares of 4D Molecular Therapeutics (FDMT).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.